Glucocorticoids play a fundamental role in the maintenance of homeostasis in mammals. Removal of the adrenals severely compromises the ability of animals to withstand fasting (for reviews see Refs. 1 and 2). Glucocorticoids exert their effects via the glucocorticoid receptor (GR), 1 predominantly by modulating gene transcription (3) (4) (5) . An attractive mode of regulation, especially in light of the coordinated effects of glucocorticoids in maintaining homeostasis, is the opposing control of the same gene in different tissues by GR. PEPCK-C gene provides an optimal model for studying this mode of regulation. The transcription of this gene is stimulated by glucocorticoids in the liver and kidney (6, 7) but is repressed in the adipose tissue (8) .
PEPCK-C catalyzes a key reaction that determines the rates of gluconeogenesis in the liver and kidney and glyceroneogenesis in the adipose tissue and liver (9) . Glyceroneogenesis, the de novo synthesis of 3-glycerophosphate from pyruvate and amino acids (via an abbreviated version of gluconeogenesis), provides this precursor for the synthesis of triglycerides (10, 11) . Recently, we have performed a targeted mutation in the adipose tissue-specific enhancer of the PEPCK-C gene in embryonic stem cells. The mutation ablated PEPCK-C gene expression in white adipose tissue of mice homozygous for this mutation and caused a decrease in the storage of triglycerides, which in some mice developed into lipodystrophy (12) . This mutation therefore established the importance of PEPCK-C and glyceroneogenesis in the homeostasis of triglycerides in the adipose tissue.
Because PEPCK-C is encoded by a unique copy gene, and is transcribed from a single promoter, it is likely that tissuespecific factors are involved in the reciprocal regulation that leads to stimulation (liver and kidney) or repression (adipose tissue) of the gene transcription in the presence of glucocorticoids. Yamamoto and colleagues (13) proposed the term composite GRE to describe a nonconsensus sequence that binds the GR with low affinity and, in turn, is capable of mediating either repression or activation of genes.
The GRE identified in the PEPCK-C gene (14) is a nonconsensus sequence that binds GR at a very low affinity and is not able by itself to transmit a transcriptional response to glucocorticoids. In fact, PEPCK-C gene promoter harbors a GR unit (GRU) containing two low affinity, nonconsensus GR-binding sites and two accessory elements, AF1 and AF2. These ele-ments do not bind steroid receptors, but their occupancy is required for the response of the PEPCK-C gene to glucocorticoids (see scheme in Fig. 2 ). The factors binding to the AF1 element are all nonsteroid nuclear receptors; these include hepatocyte nuclear factor (HNF) 4, chicken ovalbumin upstream transcription factor (COUPTF), retinoic acid receptor, retinoid X receptor (RXR), and members of the peroxisome proliferator-activated receptor (PPAR) family. The AF2 site (15) binds HNF3␤ (16, 17) and has been proposed to comprise an insulin-response element as well (18) .
To identify tissue-specific factors that are involved in the glucocorticoid-mediated repression of PEPCK-C gene transcription in adipocytes, we have employed a systematic DNase I footprinting analysis of the PEPCK-C gene promoter, using adipocyte nuclear proteins. Their functional participation in the repression has been assessed using transient transfection experiments in PEPCK-nonexpressing NIH3T3 cells. The results from these two independent experimental systems consistently identified the involvement of members of the C/EBP family, but not those of PPAR, in the GR repression of the PEPCK-C gene promoter activity. Furthermore, experiments in NIH3T3 cells revealed a hierarchical constraint of PEPCK-C gene promoter trans-activation by the separate GRU elements. Both wild type and mutant GR (incapable of binding the DNA) repress the C/EBP-mediated trans-activation by 50 -60%, regardless of whether the trans-activation is low or high. However, the repression by mutant GR critically requires an intact AF1 site in the PEPCK-C gene.
EXPERIMENTAL PROCEDURES
Materials-Dulbecco's modified Eagle's medium (DMEM), F-12, and fetal and newborn calf serum were purchased from Biological Industries, Kibutz Beit Haemek, Israel. Biosynthetic human insulin was obtained from Novo Nordisk (Denmark). Dexamethasone, the synthetic glucocorticoid hormone, was purchased from Teva, Israel Pharmaceutical Industry. Ultraspec, the commercial reagent for the preparation of tissue RNA, was purchased from Biotecx Laboratories, Inc. (Austin, TX). Radioactive signals were quantified using a PhosphorImager (Fujix BAS 1000, Fuji, Japan). Reverse transcriptase was obtained from Invitrogen. Random hexanucleotide pd(N) 6 was purchased from Amersham Biosciences, and the ribonuclease inhibitor, RNasin, was purchased from Promega (Madison, WI). The enzyme-linked immunosorbent assay kit for the determination of human somatotropin was purchased from Roche Molecular Biochemicals.
Differentiation of Adipocytes-3T3-F442A cells, obtained from Dr. Howard Green (19) , were grown to confluence in DMEM and supplemented with 10% newborn calf serum. For differentiation of the cells to adipocytes, newborn calf serum was replaced by 10% fetal calf serum; isobutylmethylxanthine was added at a final concentration of 0.2 mM, and the cells were incubated for 3 days. The cells were further incubated for at least 8 days in a medium containing 4 milliunits/ml insulin, until ϳ80 -90% of cells contained fat droplets.
Dexamethasone Treatment-Dexamethasone (10 Ϫ7 M) was added to NIH3T3 cells no later than 20 h after transfection, when expression of the reporter gene was barely detected. Cells were harvested no later than 24 h after addition of dexamethasone to prevent cell lysis. 3T3-F442A adipocytes were similarly treated with 10 Ϫ7 M dexamethasone for 16 -18 h.
RNA Isolation and RT-PCR Analysis-Total RNA was isolated from a single 100-mm cultured plate of 3T3-F442A adipocytes or from 30 mg of mouse liver using the commercial reagent Ultraspec according to the manufacturer's instructions. One g of total RNA was reverse-transcribed according to manufacturer's instructions, using the Invitrogen reverse transcriptase kit in the presence of 7.5 units/ml random hexanucleotide pd(N) 6 as primer and 1 unit/l RNasin ribonuclease inhibitor, except that the incubation was for 30 min at 42°C.
PCR was performed using the PEPCK-C primers 5Ј-CTTGTCTAC-GAAGCTCTCAG from exon 9 and 3Ј-CGTCCGAACATCCACTC from exon 10. Primers for the aP2 gene were 5Ј-CCTGGAAGCTTGTCTC-CAG from exon 1 and 3Ј-CTCTTGTGGAAGTCACGCC from exon 4. Primers for ␤-actin were the same as published previously (20) . PCR was performed in the presence of a trace of [ 32 P]dCTP (0.5 ϫ 10 6 dpm) to allow semi-quantification (20) . The PCR program included denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and elongation at 72°C for 2 min, 20 cycles each consisting of denaturation for 30 s, annealing for 1 min, and elongation for 1 min. The PCR product was separated by electrophoresis on 8% polyacrylamide gel and quantified using a PhosphorImager apparatus and visualized by its exposure to autoradiographic film.
Preparation of Nuclear Proteins-Nuclear proteins were extracted from rat liver according to Gorski et al. (21) as modified (22) . Nuclear protein extracts from adipocytes were prepared essentially as described previously (22) , except that the sucrose gradient step to further purify the nuclei was omitted. DNase I footprinting assays were performed as described previously (22) . The autoradiographic density signals of specific bands in the exposed film (see Figs. 2-4) were quantified using Fluor-S TM MultiImager with Multianalyst version 1.1 (Bio-Rad). Western Blot Analysis-5 g of nuclear proteins from adipocytes treated or untreated with dexamethasone (a synthetic glucocorticoid) were separated on 15% SDS-PAGE and transferred to nitrocellulose membrane (Protran BA 85, Schleicher & Schuell). C/EBP␣ was probed with rabbit polyclonal anti-C/EBP␣ antibody c100 diluted 1:1000 (a gift from Dr. Steven McKnight) and was detected using horseradish peroxidase-conjugated goat anti-rabbit antibody diluted 1:4000. Nuclear Y12 protein was probed with mouse anti-sm monoclonal antibody Y12 (23) (a gift from Dr. Ruth Sperling), diluted 1:10, and detected using horseradish peroxidase conjugated to affinity-purified goat anti-mouse IgG F(ab)Ј fragment diluted 1:3000 (23) . Secondary antibodies were visualized with SuperSignal West Pico chemiluminescent substrate (Pierce).
Cell Culture, Transfection Conditions, and CAT Assays-NIH3T3 cells were grown on 100-mm plates in DMEM containing 10% fetal calf serum. For transfection, cells were transferred to DMEM containing 10% newborn calf serum. Transfection was performed essentially according to Chen and Okayama (24), as described previously (25), 1 or 2 days after the cells reached confluency. Supercoiled PEPCK-CAT plasmid (2 g) and additional carrier pBlueScript DNA (Stratagene), to make a total of 12 g, were used, and the transfection efficiency was monitored as described previously (25) . Where indicated, 1 g each of the expression vectors for C/EBP␣ and PPAR␥2 together with RXR␣ or GR was used. The optimal quantity of C/EBP␤ or C/EBP␦ expression vectors added to the transfection mixture was 0.5 g each. In all cases, titration test of various concentrations of the expression vectors allowed us to choose the amounts that yielded optimal effects. Assays for chloramphenicol acetyltransferase (CAT) activity were determined 44 h after transfection, as described (25) , and quantified using a PhosphorImager apparatus. The S.E. was calculated as the S.D. divided by the square root of the number of experiments.
Plasmids Used in the Transfection Studies-The previously described plasmid 597-pck-CAT (PCK (600)-CAT) contains 597 bp of the rat PEPCK-C gene promoter region fused to the CAT reporter gene (26) . The derived 2000-pck-CAT plasmid (PCK(2000)-CAT) contains 2000 bp of the PEPCK-C gene promoter (27) . The mutated AF1 (AF1-mut), the combined mutation of GRE1 and GRE2 (mGRE1-2) (28), and the mutated AF2 (AF2-mut) (29) plasmids contain 2000 bp of the rat PEPCK-C gene promoter mutated at these sites. The mouse promoters PCK(840)-CAT and PCK(1500)-CAT contain 840 or 1500 bp upstream from the transcription start site of PEPCK-C gene promoter, derived from a mouse genomic clone, and fused to the CAT reporter gene as described previously (26) . The PCK(1500-mut)-CAT plasmid contains a site-specific mutation of the PPARE sequence. The mutation was generated by inserting the restriction sites XhoI and SmaI 3Ј and 5Ј, respectively, to the PPARE site. This enabled us to replace the PPARE site with 47 bp of the pBlueScript polylinker residing between XhoI and SmaI, except that the EcoRI site of the polylinker insert was deleted.
The DNA concentration of the constructs containing the longer PEPCK-C gene promoters was corrected to achieve the same number of molecules as that of the shorter PEPCK-C gene promoters. Expression vectors encoding adipocyte-enriched transcription factors used in this work included the following: C/EBP␣ (30) obtained from Dr. Steven McKnight; C/EBP␤ (31) from Dr. David Ron; C/EBP␦ (32) from Dr. Daniel Lane; PPAR␥2 (33) from Dr. Bruce Spiegelman; RXR␣ (34) and human GR (35) from the laboratory of Dr. Ron Evans; and rat wild type and mutant GR were a gift from Dr. Keith Yamamoto (13) .
RESULTS

Repression of PEPCK-C Expression by Glucocorticoids in
Vivo-The addition of glucocorticoids to fully differentiated 3T3-F442A adipocytes for 16 -18 h caused a strong repression of PEPCK-C gene expression as shown by the absence of its RT-PCR product (Fig. 1 ). This repression was distinct because glucocorticoids failed to inhibit the expression of the adipocytespecific aP2 gene (Fig. 1) .
DNase I Footprinting Assays-In order to assess whether GR affects the binding of nuclear proteins to specific sites in the PEPCK-C gene promoter, we systematically footprinted the gene promoter, using nuclear proteins extracted from 3T3-F442A adipocyte cells that had been incubated without or with glucocorticoids. A scheme of PEPCK-C gene promoter depicting the binding sites of transcription factors is shown (Fig. 2a) . The figure also includes the binding sites for nuclear proteins present in the liver, fetal liver (where the gene for PEPCK-C is not actively transcribed (22, 36) ), kidney, and adipocytes (Fig. 2b) . Note that nuclear proteins from the liver and adipocytes bind to most sites included within positions Ϫ70 to Ϫ1200 of the transcription start site of the PEPCK-C gene promoter. Adipocyte nuclear proteins do not bind to the P2 site (HNF-1 recognition motif) in the PEPCK-C gene promoter (37), whereas nuclear proteins from the liver bind poorly to PPARE (the PPAR recognition site (see Fig. 3b) ). Unlike the kidney and fetal liver, nuclear proteins from adipocytes and liver bind all C/EBP recognition sites. These include the CRE-1 (cAMP-response element), P3I, P4, and CRE-2 sites (CRE-2 is a CRE-like sequence). Of these, P3I binds exclusively isoforms of the C/EBP family (38) . CRE-1 and P4 sites bind AP1 as well, and CRE-1 also binds cAMP-response element-binding protein, ATF-2 (39), and ATF-3 (40) . CRE-2 binds C/EBP␣ with very low affinity but binds a nonidentified temperature-labile protein in the liver nuclear proteins (22) .
Our footprinting analysis revealed that nuclear proteins extracted from glucocorticoid-treated adipocytes failed to bind to all C/EBP recognition sites in the PEPCK-C gene promoter: CRE-1 (Fig. 2c ), P3 and P4 (Fig. 2d) , and the single C/EBP-like CRE-2 site (Fig. 2c) . The prominent inhibition of binding to all these sites occurred despite the wide spectrum of affinities of the C/EBP recognition sites to C/EBP␣, which gradually decreases from the highest affinity (CRE-1 site) to the lowest (CRE-2 site) (22, 41) . In addition, binding to the P1 site (nuclear factor 1 recognition site) in the PEPCK-C gene promoter was also inhibited (Fig. 2c ), although this is not a C/EBP recognition site. In previous studies (38) the binding of C/EBP␤ to CRE-1 has been shown to cooperate with the binding to the P1 site. Therefore, a reduced binding to CRE-1 site might have led to a secondary effect on the binding to the P1 site.
The binding of adipocyte nuclear proteins to the recognition sites of nuclear receptors in the PEPCK-C gene promoter has not been affected by the glucocorticoid treatment. Thus, binding to AF1 site (also termed P6) remained similar whether using nuclear proteins from adipocytes not treated or treated with glucocorticoids (Fig. 3a) . AF1 site is a nuclear receptor recognition site that interacts with a variety of nonsteroid nuclear receptors including HNF4, COUPTF, retinoic acid receptor, RXR, and members of the PPAR family. Similar to adipocytes, hepatic nuclear proteins also interact well with the AF1 site (Fig. 3a) .
Another non-C/EBP-binding site, which likewise has not been affected by the glucocorticoid treatment, is PPARE (the recognition site of the heterodimer nuclear receptors PPAR␥2/ RXR) (Fig. 3b) . In contrast to the adipocyte nuclear proteins, binding of hepatic nuclear proteins to the PPARE site could barely be detected (Fig. 3b) , unlike their efficient binding to the AF1 site (Fig. 3a) . Furthermore, the hypersensitive site (position Ϫ985) at the 3Ј end of the protected region appeared only in the presence of adipocyte nuclear proteins. It was undetectable both in the absence of nuclear proteins and in the presence of liver nuclear proteins (Fig. 3b) . Therefore, PPAR isoforms seem less enriched in the liver (from nonfasted rat) than they are in adipocyte nuclear proteins. To gain quantitative estimation of the glucocorticoid effect, we measured the density signals of specific bands inside and outside the protected regions of the CRE-1 (Fig. 2a) and AF1 (Fig. 3a) sites. The footprinting intensity of the CRE-1 site was quantified from the autoradiographic films by measuring the density signal of a band within the CRE-1 site (position Ϫ88 from the transcription start site of FIG. 1. Effect of the glucocorticoids on PEPCK-C gene expression in adipocytes. cDNA made from 1 g of total RNA, using random hexamer primers, was amplified by PCR (1 l out of the total 30 l of RT reaction mix), using PEPCK-C and ␤-actin primers. The PCR products from adipocytes treated with dexamethasone (A ϩ Dex) compared with the nontreated cells (A Ϫ Dex), were identified by size separation as indicated on the right-hand side of the figure. The RT-PCR products of liver PEPCK-C RNA (L) and of the adipocyte-specific aP2 gene are shown as controls.
FIG. 2.
DNase I footprint analysis of the PEPCK-C gene promoter. a, scheme of the gene promoter. The entire GRU in the proximal region of the gene promoter includes two GR-binding sites (GR) and two accessory sites, out of which the more 5Ј is AF1 and the more 3Ј is AF2 (IRS, insulin response signal) (14) . A distal element (PPARE) is homologous to the AF1 element except that it binds only PPAR and RXR (33) . Note that four structures (CRE-1, CRE-2, P3, and P4) contain C/EBP recognition sequences (22, 41) . b, binding (ϩ) and absence of binding (Ϫ) of nuclear proteins from the indicated tissues. DNase I footprinting data of adult liver (61), fetal liver (22) , kidney (61) , and adipocytes (37) are indicated. c, a 390-bp DNA fragment, spanning positions Ϫ8 to Ϫ390 of the rat PEPCK-C gene promoter was 32 P-end-labeled at the 3Ј site (position Ϫ8) of the fragment. 50,000 cpm per reaction of the labeled fragment were incubated without proteins (0Ј) or with 15 g of nuclear proteins from 3T3-F442A adipocytes not treated (A Ϫ Dex) or treated overnight with Dexamethasone (A ϩ Dex). The lane on the left (seq) designates sequencing of A ϩ G, which enabled the identification of the regions protected by protein binding to CRE-2 and P1/CRE-1 sites. The binding regions are marked by the positions 5Ј to the transcription start site. Bands used for quantification of the signals (see Fig. 3c ), a band at position Ϫ88 (within the CRE-1 protected area) and at position Ϫ160 (outside the protected area) (b), are marked by arrows on the right. d, the same probe as described in c was used, except that a longer separation enabled the identification of regions protected by protein binding to the C/EBP recognition sites P3 and P4 indicated in the figure by their positions 5Ј to the transcription start site.
the PEPCK-C gene) and a band outside, at position Ϫ160 (both marked by arrows). Likewise, the footprinting intensity of the AF1 site was quantified by measuring the density signals of two bands inside (positions Ϫ445 and Ϫ446) and a band outside (position Ϫ457) the AF1 site. The ratios between the density signals inside and outside the protected region were computed. The ratios obtained from the footprinting done without nuclear proteins were arbitrarily set at 10 and used to normalize other ratios of the footprinting done in the presence of nuclear proteins. These measurements have clearly assessed that dexamethasone treatment interfered with the adipocyte nuclear protein footprinting of the CRE-1 site (Fig. 3c) but not with the footprinting of the AF1 site (Fig. 3d) .
Transcription of the gene for C/EBP␣ is also repressed by glucocorticoids but only for a few hours (32) . Yet this repression might lead to a longer lasting reduction of C/EBP␣ protein concentration in adipocyte nuclei (32) , resulting in an apparent, rather than real, interference of binding to its recognition sites. Therefore, we determined whether the concentration of C/EBP␣ in nuclei corresponded to the observed diminished footprinting of the PEPCK-C gene promoter.
C/EBP␣ Level in Extracted Adipocyte Nuclear Proteins-The concentration of C/EBP␣ in the adipocyte extracts of nuclear proteins used for footprinting was determined by Western blot assay. The hormonal treatment diminished the nuclear concentration of C/EBP␣ by 30% when normalized to the level of the Y12 nuclear protein (Fig. 4a) . Whether this reduced concentration of C/EBP␣ accounted for the inhibited footprinting of nuclear proteins from glucocorticoid-treated adipocytes was assessed. Thus, we used lower amounts of nuclear proteins extracted from untreated adipocytes (10 (2/3) and 7.5 g (1/2)), compared with the whole amount (15 g), to footprint the gene promoter region containing the CRE-1, P1, and CRE-2 sites. This region enabled us to assay the site with the highest affinity for C/EBP binding (CRE-1) and the site with the lowest affinity for C/EBP binding (CRE-2). The analysis showed that 10 g of nuclear proteins footprinted all three sites (Fig. 4b) . Footprinting of the CRE-1 site was quantified as detailed above for Fig. 2c . Thus, the ratio in the absence of proteins was set at 10, relative to a ratio of 2.5 obtained with 10 g of protein and a ratio of 8.5 obtained with 7.5 g of protein (Fig. 4c) . The dexamethasone effect on CRE-1 footprinting (Fig. 2c ) that was likewise quantified yielded a ratio of 1.7 in the presence of 15 g of nuclear proteins from untreated adipocytes, and 15.8 in the presence of 15 g of nuclear proteins from dexamethasonetreated adipocytes (Fig. 3c) . In contrast, footprinting the AF1 site yielded similar ratios (2.7 and 3.3, respectively) using 15 g of nuclear proteins from untreated or dexamethasonetreated adipocytes (Fig. 3d) . We therefore conclude that in addition to lowering the level of C/EBP␣ in the nucleus, the hormonal treatment interfered with the binding to their recognition sites in the PEPCK-C gene promoter.
Transient Transfection Experiments in NIH3T3 Cells-The involvement of adipocyte-enriched transcription factors in the repression of PEPCK-C gene transcription by glucocorticoids was further assessed using transient transfection assays in NIH3T3 cells. Although these cells do not express PEPCK-C or the adipocyte-specific transcription factors PPAR␥2 or C/EBP␣ (42), co-transfecting expression vectors coding for PPAR␥2 and RXR␣ (PPAR␥2/RXR) were reported to stimulate transcription from the PEPCK-C gene promoter in these cells (33) . We have compared the stimulation of the PEPCK-C gene promoter activity by PPAR␥2/RXR and by C/EBP␣ expression vectors using PEPCK-CAT chimeric genes driven either by 600 (PCK(600)-CAT) or 2000 bp (PCK(2000)-CAT) of the PEPCK-C gene promoter (27) . PPAR␥2/RXR preferentially stimulated the transcription from PCK(2000)-CAT PEPCK-C gene promoter, whereas C/EBP␣ preferentially and markedly stimulated transcription from the PCK(600)-CAT gene promoter (Fig. 5a ). The latter is most likely because of the localization of a cluster of C/EBP recognition sites in the proximal region of the PEPCK-C gene promoter (9) . For orientation see the scheme of the PEPCK-C gene promoter (Fig. 2a) . In addition to C/EBP␣, other members of the C/EBP family also trans-activated the PEPCK-C gene promoter but to a lesser extent. C/EBP␣ was the most effective; C/EBP␤ was half as effective, and C/EBP␦ was the least effective. There was a 5-fold difference in the magnitude of stimulation between C/EBP␣ and C/EBP␦ (Fig.  5b) . We then determined the effect of GR and its hormone (dexamethasone) on the level of trans-activation of the PCK(600)-CAT gene promoter by co-transfected C/EBP␣, C/EBP␤, or PPAR␥2/RXR. Co-transfection of GR expression vector and the addition of dexamethasone for the last 24 h after transfection inhibited (by about 60%) the activation of transcription from the PEPCK-C gene promoter either by C/EBP␣ or by C/EBP␤. In contrast, there was no effect of GR and dexamethasone on the trans-activation by PPAR␥2/RXR of either PCK(600)-CAT (Fig. 5c) or PCK(2000)-CAT (Fig. 5d ) gene promoters.
The preferential PPAR␥2/RXR trans-activation of the longer region of the PEPCK-C gene promoter, either PCK(2000)-CAT (rat) or PCK(1500)-CAT (mouse) gene promoters compared with PCK(600)-CAT (rat) and PCK(840)-CAT (mouse) (Figs. 5a and 6a), is due to the two PPAR␥2/RXR recognition sites (a proximal AF1 side and a distal PPARE site). Moreover, mutation of the PPARE sequence in PCK(1500)-CAT gene promoter (mouse PCK(1500-mut)-CAT) abolished its response to PPAR␥2/RXR, although it contained the proximal AF1-binding site (Fig. 6a) . Note that the sequence of PEPCK-C gene promoter is highly preserved between the rat (43) and the mouse (44) . Furthermore, mutation of the PPARE sequence specifically ablated PEPCK-C gene expression in the adipose tissue in vivo as shown with the mutated rat PEPCK-C transgene in transgenic mice (45) and the targeted mutation in the mouse endogenous PEPCK-C gene (12) . In contrast, mutation of the proximal PPAR␥2/RXR-binding site (AF1 site) in the context of PCK (2000)-CAT gene promoter markedly increased the PPAR␥2/RXR trans-activation of the gene promoter (Fig. 6b) . The constraining features of the wild type AF1 site of the PEPCK-C gene promoter in NIH3T3 cells have been studied recently in detail by Eubank et al. (46) . These authors showed that the AF1 site tightly binds the nuclear receptor COUPTF II whose expression vector inhibited the PPAR␥2/RXR-mediated trans-activation of the PEPCK-C gene promoter via the AF1-binding site (46) . These features of AF1 site are not shared by other GRU elements, because mutation of the AF2 site had no effect on the trans-activation of PCK (2000)-CAT by PPAR␥2/ RXR (Fig. 6b) .
C/EBP␣-mediated trans-activation of the PCK(2000)-CAT chimeric gene is also constrained (Fig. 6c) . However, unlike the trans-activation by PPAR␥2/RXR, in this case mutations of any single element of the GRU (14) , AF1, AF2, and GRE1-2 of PCK(2000)-CAT chimeric gene, enhanced the C/EBP␣-mediated trans-activation of the gene promoter by 3-4-fold (Fig. 6c) . Therefore, unlike PPAR␥2/RXR, not only the AF1 site but the entire GRU domain constrains the C/EBP␣ trans-activation of Ϫ7 M dexamethasone. The equally blotted amounts of proteins were verified after stripping the membrane and re-probing with anti-Y12 antibody. The percent reduction of C/EBP␣ nuclear level by dexamethasone treatment is indicated above. b, footprinting analysis of the same probe as described in Fig. 2c . The probe was incubated without proteins (0Ј) or with the indicated amounts (15, 10, or 7.5 g) of nuclear proteins extracted from adipocytes not treated with dexamethasone. c, the ratio between the density signal of a band at position Ϫ88 (within the CRE-1 protected region) and a band at position Ϫ160 outside the protected area (marked by arrows on the right of the footprinting in b) was plotted against the amounts of nuclear protein used. The ratio in the absence of proteins was set at 10. the PCK(2000)-CAT chimeric gene. Because each of the elements comprising the GRU constrained the C/EBP␣ transactivation of the PCK(2000)-CAT chimeric gene, we asked whether-binding of GR to the PEPCK-C gene promoter is required for its mediated repression. To this end, the capacity of the wild type rat GR was compared with its counterpart rat mutant GR that is incapable of binding to the DNA (13, 47) to inhibit the C/EBP␣-mediated trans-activation of PCK (2000)-CAT. The data showed that either wild type or mutant rat GR equally repressed the stimulation of transcription from the PEPCK-C gene promoter by C/EBP␣ (Fig. 7a) .
Finally, we have assessed whether the enhanced C/EBP␣-mediated transcriptional stimulation of the GRU-mutated series of PCK(2000)-CAT could be repressed by GR and whether the mutant GR was also effective. The wild type GR repressed the C/EBP␣-mediated stimulation of the GRU series of PCK(2000)-CAT mutants to a similar extent as that of the wild type (about 50%) (Fig. 7b) . The mutant GR repressed the stimulation of the wild type and GRE1-2 mutant of PCK(2000)-CAT to a similar extent, less so the AF2 mutant, but completely failed to repress the stimulation of PCK (2000)-CAT-AF1 mutant (Fig. 7b) . Therefore, the AF1 site is required for the repression by mutant GR but not by the wild type GR (Fig. 7b) . In fact, the AF1 site emerges as an inherent constraining element on transcription from the PEPCK-C gene promoter because it markedly restrains the trans-activation of PCK (2000)-CAT gene promoter activity either by PPAR␥2 or by C/EBP␣ (Fig. 6,  b and c) . Moreover, intact AF1 is also required for the mutant GR-mediated repression of C/EBP␣ trans-activation of the PEPCK-C gene promoter. When AF1 is mutated, the repression by mutant GR is abolished (Fig. 7b ).
DISCUSSION
Our results shed light on the involvement of transcription activators from the C/EBP family, but not those from the PPAR family, in the glucocorticoid-mediated repression of PEPCK-C gene transcription in adipocytes. Glucocorticoid treatment of 3T3-F442A adipocytes led to a reduced nuclear concentration of C/EBP␣, in addition to a markedly diminished binding of nuclear proteins to the C/EBP recognition sites (but not to the PPAR/RXR recognition sites) in the PEPCK-C gene promoter. Previous studies from our laboratory (26) documented a requirement for the C/EBP recognition sites of the PEPCK-C gene promoter that were crucial for its basal activity in adipocytes. Transient transfection in NIH3T3 cells revealed that GR together with glucocorticoids partially inhibited the C/EBPmediated, but not PPAR␥2-mediated, trans-activation of PEPCK-C gene promoter. We have thus described the involvement of members of the C/EBP family in the adipocyte-specific glucocorticoid repression of PEPCK-C gene expression. This occurs in at least two ways: (a) by reducing the concentration of C/EBP␣ in adipocyte nuclei, and (b) interfering with the binding of nuclear proteins to the C/EBP recognition sites in the DNA and as a consequence of, or in addition to, inhibiting the trans-activation of PEPCK-C gene promoter by C/EBP isoforms. Clearly, using nuclear proteins from the PEPCK-expressing adipocytes and transient transfection in the PEPCKnonexpressing NIH3T3 cells comprised two independent experimental approaches and systems, both of which consistently revealed the involvement of C/EBP but not PPAR activators in the glucocorticoid repression of PEPCK-C gene transcription. However, because GR succeeded to inhibit the C/EBP trans-activation only by 60%, it is likely that additional factors beside members of C/EBP family participate in PEPCK-C gene transcription in the adipocytes.
Experiments using NIH3T3 cells have disclosed a hierarchical regulation of PEPCK-C gene transcription, in particular the constraint on the gene promoter response to C/EBP-mediated activation by the GRU element in the PEPCK-C gene promoter. Mutating any single element within the GRU relieves this constraint, and the trans-activation by C/EBP␣ is markedly elevated. This is different from trans-activation by PPAR␥2/ RXR, which is also constrained, but in this case, it is not exerted via each element of the GRU but exclusively by the AF1 site. In that sense, the AF1 site has emerged as a unique element whose mutation elevates by 4-fold the response of PCK(2000)-CAT to either PPAR␥2/RXR or C/EBP␣. These constraining features of AF1 are accentuated by the very modest response of this site to PPAR␥2/RXR activation of transcription from the PEPCK-C gene promoter (Fig. 6a) . The main PPAR␥2/ RXR-responsive element is PPARE (Fig. 6a) that comprises an adipose tissue-specific enhancer, as has been shown previously in transgenic mice (45) . Furthermore, a targeted mutation of PPARE in embryonic stem cells resulted in ablation of PEPCK-C gene expression in the white adipose tissue of offspring mice homozygous for the mutation (12) .
Is the AF1 site involved in the GR repression of the C/EBP␣-mediated trans-activation of PCK (2000)-CAT? The present data seem to support such involvement. Initially, our results have established that the GR repression does not require binding to the DNA. A GR mutated in the zinc finger (13) , making it incapable of binding the DNA, was as active as wild type in repressing the C/EBP␣ stimulation. Subsequently, we have assessed that the wild type GR equally repressed the wild type PCK(2000)-CAT and derived mutated GRU series, whereas the mutant GR repressed the mutated GRE1-2 sites and, to a lesser extent, the mutated AF2 site of PCK (2000)-CAT. However, mutation of the AF1 site abolished the capability of the mutant GR to repress the C/EBP-mediated trans-activation. Because the mutated AF1 site did not hinder the repression by wild type GR, we suggest that the AF1 site undertakes a docking role to facilitate the mutant GR-mediated repression of the PCK(2000)-CAT gene promoter. Thus, these observations expand the hierarchy of regulation to strongly suggest that, in addition to its constraint features, the wild type AF1 site is crucial for the hormonal repression.
Because the repression by GR of the C/EBP-mediated transactivation does not require DNA binding of the receptor, the GR probably inhibits trans-activation of PEPCK-C gene transcription via protein-protein interactions. This notion is supported by the fact that the percent repression by GR of the C/EBP␣-mediated activation of transcription remained 50 -60% whether the activation was low (wild type PCK(2000)-CAT gene promoter) or elevated by 3-4-fold (GRU-mutated series of PCK(2000)-CAT gene promoter).
Evidence of cross-talk between members of the C/EBP family and GR has been documented in numerous systems. Members of the C/EBP family have been shown to bind directly to the ligand binding domain of a number of nuclear receptors, including GR (see Refs. 48 and 49 and for review see Refs. 5 and 50). These interactions resulted either in induction or inhibition of the target genes and did not necessarily involve binding of GR to the DNA (48, 49) . Alternatively, binding of C/EBP␤ to the DNA binding domain of GR has been implicated recently in the GR repression of the vitellogenin gene transcription in hepatocytes from the rainbow trout. The vitellogenin gene promoter lacks a GR-binding site (51) .
Beyond the molecular aspects of the glucocorticoid repression of PEPCK-C gene transcription in adipose tissue, its physiological significance has gained new relevance. Metabolic studies have recently documented very substantial rates of glyceroneogenesis in the liver of both rats and humans during fasting (52, 53) or after ingestion of a diet high in protein but devoid of carbohydrate (52) . These findings shed new light on the metabolic significance of the reciprocal control of PEPCK-C gene transcription by glucocorticoids. PEPCK-C activity catalyzes the rate-limiting step of both gluconeogenesis and glyceroneogenesis, hence regulating both pathways. This has been verified by deletion of the PEPCK-C gene in mice, resulting in neonatal lethality from hypoglycemia (54) . In addition, a targeted mutation of the adipose tissue-specific PPAR␥2-binding site of the PEPCK-C gene promoter, which selectively ablates gene expression in white adipose tissue, caused a marked diminution of glyceroneogenesis in this tissue. Mice homozygous for this mutation lost lipid from adipose tissue even to the extent of lipodystrophy, attesting to the metabolic significance of PEPCK-C and glyceroneogenesis in the adipose tissue (12) . Moreover, a recent adipocyte-specific knockout of glucose transporter 4, required for glucose metabolism in the adipose tissue, generated mice exhibiting features of noninsulin-dependent diabetes mellitus without a loss of triglycerides from adipose tissue (55) . Finally, Franckhauser et al. (56) overexpressed a chimeric gene containing the PEPCK-C structural gene linked to the aP2 promoter in mice resulting in obesity in adult mice. Taken together, these results further emphasize the crucial role of PEPCK-C and glyceroneogenesis in maintaining lipid homeostasis in the adipose tissue. Therefore, it is conceivable that hormonally mediated alterations of PEPCK-C gene expression ultimately regulate glyceroneogenesis in both liver and adipose tissue.
Lipid is released from the adipose tissue as free fatty acids and from the liver as triglycerides. Thus, glyceroneogenesis affects lipid metabolism in opposite ways in the two tissues; it restrains fat release from adipose tissue (57) and enhances it from the liver (58) . It has been shown in rats that adrenalectomy enhances glyceroneogenesis and diminishes free fatty acid release from incubated epididymal fat pads (59, 60) . In a reciprocal experiment, the addition of dexamethasone to cultured hepatocytes stimulated the synthesis of triglycerides and apolipoproteins E and B, as well as stimulating the release of very low density lipoproteins to the medium (58) . How then is lipid homeostasis coordinated between the two tissues? We propose that the reciprocal regulation of PEPCK-C gene transcription by glucocorticoids provides a mechanism for such coordination because it represses PEPCK-C gene transcription in the adipose tissue and simultaneously enhances it in the liver. Experiments to further prove this hypothesis in vivo are under way.
